Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.

ABSTRACT:

Background

Osimertinib yields significant tumor responses and durations of progression-free survival (PFS) in patients with acquired T790M mutations. However, the evidence supporting liquid biopsy-guided treatment is still limited. This study examined the real-world benefits of osimertinib in patients with tissue or plasma T790M mutations.

Methods

From January 2016 to June 2018, a total of 183 non-small-cell lung cancer patients were enrolled. The presence of the T790M mutation was assessed by either tissue or plasma. The PFS, overall survival, and tumor response rates of the patients were calculated and compared with those of previous clinical trials.

Results

T790M mutations were detected in 51.5% of the patients, including 64 of 140 (45.7%) who underwent liquid biop

SUBMITTER: Su PL 

PROVIDER: S-EPMC6792511 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature